Evidence map›Paper›PMID 37919605›Full record

ArticleLeukemia2023

Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic target.

Yu-Hung Wang, Chien-Chin Lin, Kristian Gurashi, Bettina Wingelhofer, Fabio M R Amaral, Chi-Yuan Yao, Hsin Ting Hsieh, Ming Chih Liu, Hsin-An Hou, Wen-Chien Chou and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yu-Hung WangDivision of Hematology, National Taiwan University Hospital, Taipei, Taiwan.ORCID http://orcid.org/0000-0003-4483-5627
Chien-Chin LinDivision of Hematology, National Taiwan University Hospital, Taipei, Taiwan. jake9665@gmail.com.
Kristian GurashiEpigenetics Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, UK.
Bettina WingelhoferLeukaemia Biology Laboratory, Cancer Research UK Manchester Institute, Manchester, UK.
Fabio M R AmaralLeukaemia Biology Laboratory, Cancer Research UK Manchester Institute, Manchester, UK.
Chi-Yuan YaoDivision of Hematology, National Taiwan University Hospital, Taipei, Taiwan.ORCID http://orcid.org/0000-0001-5052-9445
Hsin Ting HsiehDepartment of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
Ming Chih LiuDepartment of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
Hsin-An HouDivision of Hematology, National Taiwan University Hospital, Taipei, Taiwan.ORCID http://orcid.org/0000-0003-2780-4845
Wen-Chien ChouDivision of Hematology, National Taiwan University Hospital, Taipei, Taiwan.ORCID http://orcid.org/0000-0003-2967-698X
Kiran BattaEpigenetics Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-3494-0979
Daniel H WisemanEpigenetics Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0003-0715-1402
Hwei-Fang TienDivision of Hematology, National Taiwan University Hospital, Taipei, Taiwan. hftien@ntu.edu.tw.ORCID http://orcid.org/0000-0002-1384-5593

Funding

Cancer Research UK RCCASF-NOV22/100001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Myelodysplastic SyndromesAzacitidineHumansPrognosisAzacitidine

Identifiers

PMID37919605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.